Journal of Clinical Oncology
Articles in this Issue
Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial.
4052 Background: Due to the lack of prospective randomized controlled clinical studies, current guidelines do not recommend postoperative adjuvant therapy...
Clinical characteristics and determinants of primary refractory metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study.
4549 Background: Immune checkpoint inhibitor (ICI)-based regimens, including ICI + ICI and ICI+VEGF-targeted therapy (VEGF-TT), represent the current stan...
An AI-powered complete blood count panel for high-grade cervical lesion identification: A multicentric retrospective study.
e17535 Background: Early detection and accurate risk stratification of high-grade cervical lesions (HSIL) are crucial for effective treatment and improved...
Accuracy of large language models for matching cancer patients to biomarker-driven clinical trials based on molecular profiles.
e13627 Background: Clinical trials are an important treatment option for cancer patients, in particular if standard treatment modalities have been exhaust...
Global trends of early onset cancers (15-49 years) 1990-2021 and projection to 2040.
e22584 Background: The global burden of early onset cancer (EOC)(15–49 years) is increasing, and understudied. We aim to investigate the incidence and mor...
Incidence of infections, cardiac events, neurological toxicity and cytokine response syndrome (CRS) in patients treated with chimeric antigen receptor (CAR) T cell therapy: A 3-year nationwide analysis.
7018 Background: CAR-T cell therapy represents a notable advancement in treating relapsed/refractory (R/R) hematological malignancies. Adverse events incl...
Evaluating response bias in RECIST 1.1: Impact on non-target lesion assessment in oncology.
e13691 Background: In oncology, the RECIST 1.1 criteria serve as a cornerstone for assessing tumor response to therapeutic interventions. The criteria inv...
Efficacy of cardioprotective therapies in preventing cardiotoxicity in breast cancer patients treated with anthracyclines: A systematic review and meta-analysis.
e15123 Background: Cancer therapy-related cardiac dysfunction (CTRCD), particularly in patients receiving anthracyclines (such as doxorubicin or epirubici...
Enhanced dysplasia detection in inflammatory bowel disease: A comprehensive meta-analysis of dye-based chromoendoscopy versus high-definition white light endoscopy.
e15135 Background: Patients with inflammatory bowel disease (IBD), particularly those with long-standing ulcerative colitis, are at a higher risk of devel...
Retrospective registry for acral melanoma in Lebanon: A 12-year single-center experience in the MENA region.
e21599 Background: Acral melanoma (AM) is a rare, aggressive melanoma subtype that primarily affects non-hair-bearing skin, such as the palms, soles, and...
Biosafety analysis from the skin cancer cohorts in the IGNYTE clinical trial of RP1.
9534 Background: RP1 (vusolimogene oderparepvec) is an HSV–based oncolytic immunotherapy administered intratumorally. RP1 + nivolumab (nivo) has demonstra...
Successful intervention to bridge the knowledge gap in recognizing and managing chemotherapy hypersensitivity reactions among oncology fellows in southeast Michigan.
9022 Background: Recognizing hypersensitivity reactions (HSRs) to paclitaxel and carboplatin in patients receiving multi-drug chemotherapy regimens combin...
Colorectal cancer (CRC): Now a disease of young!
e15703 Background: Rate of CRC is increasing in younger population. Here, we aim to study the demographics of young patients (age < 50) with CRC using...
Prevalence of immune-related adverse events (irAEs) and association with symptom distress score by Edmonton Symptom Assessment System (ESAS) in solid cancer patients receiving immune checkpoint inhibitor (ICI) therapy.
e23191 Background: Immune-related adverse events (irAEs) after immunotherapy are unique and unpredictable, differing from chemotherapy or targeted therapy...
Predication of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD1 inhibition directly from histopathology slides using inferred transcriptomics.
2630 Background: Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) not amenable to local therapy is treated with programmed death (P...
Five-year outcomes of SABR in intermediate- and high-risk prostate cancer without ADT.
5101 Background: Stereotactic ablative body radiotherapy (SABR) is emerging as a prominent treatment option for localized prostate cancer (PCa). Most exis...
Evaluating the Khorana score in advanced EGFR-mutated NSCLC patients receiving first-line osimertinib.
e20634 Background: Venous thromboembolism (VTE) poses a significant risk in patients with non-small cell lung cancer (NSCLC), particularly those with driv...
A single center, single arm, prospective clinical study initiated by a researcher on the efficacy and safety of FCN-159 in the treatment of pediatric patients with type 1 neurofibromatosis associated with symptomatic and inoperable plexiform neurofibromatosis: Mid-term study report.
e22013 Background: Data from some clinical studies have shown that MEK inhibitors have obtained effective results in the treatment of patients with inoper...
A pilot single-arm, pragmatic trial in progress of in-home versus in-clinic subcutaneous nivolumab administration through Cancer Care (connected access and remote expertise) Beyond Walls (CCBW) program.
TPS1657 Background: Cancer treatments are traditionally administered in clinical settings, which can isolate patients from their familiar environments and...
A phase II trial of pemetrexed plus oxaliplatin as ≥2 <sup>nd</sup> -line therapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin based chemotherapy.
e16240 Background: Gemcitabine/cisplatin (GP)-based chemotherapy (CTx) has been the 1 st -line CTx for patients (pts) with advance...
Bevacizumab, TAS-102, and irinotecan in oxaliplatin and fluoropyrimidine pre-treated metastatic colorectal cancer (BEV-TASIRI): A single-arm, prospective, multicenter study and comparison with BEV-FOLFIRI/XELIRI using inverse probability of treatment weighting.
e15571 Background: The efficacy of second line bevacizumab and FOLFIRI or irinotecan is limited for metastatic colorectal cancer (mCRC) after oxaliplatin...
Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
TPS2100 Background: GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Ph...
Diagnosis and follow-up of immune-related hypophysitis with MRI of pituitary gland.
e24087 Background: Immune checkpoint inhibitors (ICIs) have transformed the prognosis of many solid malignancies. However, their use has also been associa...
Safety, tolerability, and preliminary efficacy results of a phase 1 study of LB2102, a dnTGFβRII armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC).
8104 Background : Delta-like- ligand 3 (DLL3) is a promising therapeutic target for SCLC and other neuroendocrine tumors. Here, we present pre...
Comparison outcome of transarterial chemoembolization combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib as first-line therapy for advanced hepatocellular carcinoma.
4141 Background: Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic therapy for advanced hepatocellular carcinoma (HCC...